The 60-second version of Gayatri BioOrganics Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
No clear supporting case emerges from the available numbers.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| EBITDA | -₹1 Cr | -₹1 Cr | -₹0 Cr | -₹1 Cr | — |
| PAT (Net Profit) | -₹1 Cr | -₹1 Cr | -₹1 Cr | -₹1 Cr | — |
| EPS | ₹-0.13 | ₹-0.09 | ₹-0.09 | ₹-0.14 | — |
| Total Debt | ₹36 Cr | ₹36 Cr | ₹37 Cr | ₹37 Cr | +1.2% |
| Free Cash Flow | -₹1 Cr | -₹1 Cr | -₹1 Cr | -₹0 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| PIDILITE INDUSTRIES LTD | 57.8x | 24.4% |
| SRF LTD | 33.8x | 15.4% |
| UPL LIMITED | 21.5x | 6.1% |
Gayatri BioOrganics Limited owes more than it owns. Whatever the operating numbers show, the equity is a residual claim on a business with negative net worth, and that question has to be settled before any of the rest is worth weighing. 4 high-severity red flags sit above this conclusion and should be read first.